BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.

Bayer launches Felujit fungicide for paddy cultivation, offering superior protection against sheath blight with dual-action ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer ...

Bayer receives UK MHRA approval for Lynkuet to treat moderate to severe vasomotor symptoms associated with menopause: Berlin Saturday, July 12, 2025, 10:00 Hrs [IST] Bayer announc ...

Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective ...

Berlin: Bayer has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA, regulatory authority ...

The U.S. Supreme Court asked President Donald Trump's administration on Monday for its views on Bayer's bid to sharply limit ...

The Ministry of Business and Made in Italy has awarded Bayer Italia the "Excellence of the Production System and Made in ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

Bayer seeks European marketing authorization for investigational contrast agent, gadoquatrane: Berlin Friday, July 11, 2025, 11:00 Hrs [IST] Bayer announced the submission of a ma ...